Event

Awamedica to Sponsor the 1st Endocrinology Iraqi–Kurdistan Summit

April 23, 2026

The 1st Endocrinology Iraqi–Kurdistan Summit is scheduled for 9–10 April at Erbil International Hotel. The meeting will focus on a case-based approach to current topics in endocrinology and is expected to convene specialists, physicians, and healthcare professionals involved in the management of endocrine disorders.

Awamedica will participate in the summit as an event sponsor. The company’s presence reflects its engagement with national scientific activities that support continuing medical education and professional dialogue within the healthcare community.

Scientific gatherings of this nature provide a structured environment for knowledge exchange, discussion of clinical practice updates, and collaboration among healthcare stakeholders. Further updates will be shared following the event.

Blog

Phase IV Post-Marketing Surveillance: Monitoring Safety After Regulatory Approval

Phase IV studies, also known as post-marketing surveillance, evaluate the long-term safety and effectiveness of medicines after regulatory approval. These studies contribute to ongoing benefit–risk assessment in real-world clinical settings.

Drug Recalls: Regulatory Process and Manufacturer Responsibilities

Drug recalls are structured regulatory actions taken to address quality, safety, or labeling concerns associated with medicinal products. Clear procedures and defined responsibilities ensure patient protection and supply chain integrity.

Safe Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Gastrointestinal and Cardiovascular Considerations

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation management. Appropriate patient selection and risk assessment are essential to minimize gastrointestinal and cardiovascular complications.

How FDA and EMA Issue Safety Alerts: Regulatory Communication in Pharmacovigilance

Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issue safety alerts to communicate emerging risks associated with medicinal products. These alerts support timely risk mitigation and informed clinical decision-making.

1 of 3